Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients
Arthritis Rheumatol 2024 doi: 10.1002/art.42846 Epub ahead of print https://pubmed.ncbi.nlm.nih.gov/38481002/
This post hoc analysis of ORAL Surveillance showed that incidence of venous thromboembolism (VTE) events was higher in patients with RA treated with tofacitinib (10>5mg BID) versus TNFi. Across treatments, VTE risk factors (age, BMI, and VTE history) were aligned with previous studies in the general RA population.
Charles-Shoeman, et al. identified 66 patients from the ORAL Surveillance study that experienced a VTE event during the study period: 18 were treated with tofacitinib 5mg BID, 36 with tofacitinib 10mg BID, and 12 with TNFi. Post hoc, cumulative probabilities, and incidence rates were estimated for adjudicated VTE, deep vein thrombosis, and pulmonary embolism.
Keywords:
